PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage.
Celiac disease (CD) is an immune-mediated disorder triggered by the ingestion of wheat gliadin and related proteins in genetically predisposed individuals. To find a proteomic CD diagnostic signature and to gain a better understanding of pathogenetic mechanisms associated with CD, we analyzed the intestinal mucosa proteome alterations using two dimensional difference gel electrophoresis (2D-DIGE) coupled with matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF ms) of CD patients with varying degrees of histological abnormalities defined by Marsh criteria and controls. Our results clearly evidenced the presence of two groups of patients: Group A, including controls and Marsh 0-I CD patients; and Group B, consisting of CD subjects with grade II-III Oberhuber-Marsh classification. Differentially expressed proteins were involved mainly in lipid, protein and sugar metabolism. Interestingly, in Group B, several downregulated proteins (FABP1, FABP2, APOC3, HMGCS2, ACADM and PEPCK) were implicated directly in the peroxisome proliferator-activated receptor (PPAR) signaling pathway. Moreover, Group B patients presented a deregulation of some proteins involved in apoptosis/survival pathways: phosphatidylethanolamine-binding protein 1 (PEBP1), Ras-related nuclear protein (Ran) and peroxiredoxin 4 (PRDX4). PEBP1 downregulation and RAN and PRDX4 upregulation were associated with more severe tissue damage. Likewise, IgMs were found strongly upregulated in Group B. In conclusion, our results indicate that a downregulation of proteins involved in PPAR signaling and the modulation of several cancer-related proteins are associated with the highest CD histological score according to Oberhuber-Marsh classification.
Simula
Maria Paola
MP
Experimental and Clinical Pharmacology Unit, CRO Centro diRiferimento Oncologico, IRCCS National Cancer Institute, AVIANO (PN), Italy.
Cannizzaro
Renato
R
Canzonieri
Vincenzo
V
Pavan
Alessandro
A
Maiero
Stefania
S
Toffoli
Giuseppe
G
De Re
Valli
V
D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000378:metabolism; D002446:Celiac Disease / Q000378:metabolism* / Q000473:pathology*; D016000:Cluster Analysis; D015536:Down-Regulation; D004386:Duodenum / Q000378:metabolism / Q000473:pathology; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D006801:Humans; D015151:Immunoblotting; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D047492:Peroxisome Proliferator-Activated Receptors / Q000378:metabolism*; D025341:Principal Component Analysis; D015203:Reproducibility of Results; D015398:Signal Transduction; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D015854:Up-Regulation
D015415:Biomarkers; D047492:Peroxisome Proliferator-Activated Receptors
Nature. 2000 May 25;405(6785):421-4
10839530
Cancer Res. 2009 Feb 1;69(3):1240; author reply 1240
19176393
Proteomics Clin Appl. 2008 Sep;2(9):1290-9
21136923
Mol Cancer Ther. 2007 Apr;6(4):1379-86
17431116
Biochem Biophys Res Commun. 2003 Feb 7;301(2):583-90
12565903
J Pathol. 1977 Apr;121(4):219-23
327040
Nat Rev Immunol. 2002 Oct;2(10):748-59
12360213
Nature. 2000 Nov 2;408(6808):57-63
11081504
Adv Anat Pathol. 2009 Sep;16(5):290-306
19700939
Autoimmun Rev. 2008 Sep;7(8):644-50
18589004
Adv Cancer Res. 2004;91:169-200
15327891
Gut. 2003 Jul;52(7):960-5
12801951
Genome Res. 2007 Oct;17(10):1537-45
17785539
J Immunol. 2004 May 1;172(9):5790-8
15100326
Mol Cell Biol. 2001 Nov;21(21):7207-17
11585904
Baillieres Clin Gastroenterol. 1997 Sep;11(3):485-507
9448912
Arch Intern Med. 2003 Feb 10;163(3):286-92
12578508
Immunity. 1998 May;8(5):591-9
9620680
Endocr Rev. 1999 Oct;20(5):649-88
10529898
Mod Pathol. 2005 Aug;18(8):1134-44
15803187
Mol Med. 2009 May-Jun;15(5-6):173-82
19209238
Lancet. 1994 Jan 22;343(8891):200-3
7904667
J Biol Chem. 1997 Dec 5;272(49):30952-61
9388242
Gastroenterology. 1992 Jan;102(1):330-54
1727768
J Exp Med. 2009 Jan 16;206(1):69-78
19139170
J Clin Invest. 2001 Dec;108(11):1667-75
11733562
Eur J Gastroenterol Hepatol. 1999 Oct;11(10):1185-94
10524652
Proteomics. 2006 Oct;6(20):5650-61
16972299
J Immunol. 2002 Mar 15;168(6):2795-802
11884448
Lancet. 2009 Apr 25;373(9673):1480-93
19394538
J Immunol. 2009 Apr 1;182(7):4158-66
19299713
Clin Exp Immunol. 2007 Jun;148(3):402-9
17335557
J Mol Med (Berl). 2003 Jun;81(6):373-9
12743709
Gut. 2003 Aug;52(8):1211-4
12865284
J Neurosci Res. 2003 Feb 1;71(3):315-25
12526021
Gut. 2010 Mar;59(3):311-9
19951908
Mol Cell Biochem. 1993 Jun 9-23;123(1-2):93-100
8232272
Cancer Res. 2008 Mar 15;68(6):1826-33
18339863
Trends Immunol. 2007 Dec;28(12):551-8
17981503
Eur J Pharmacol. 2000 Dec 1;409(1):19-29
11099696
Gastroenterology. 2003 Sep;125(3):730-45
12949719
Gastroenterology. 1992 Mar;102(3):751-9
1537512
Baillieres Clin Gastroenterol. 1995 Jun;9(2):273-93
7549028
J Biol Chem. 1999 Nov 5;274(45):32048-54
10542237
Am J Gastroenterol. 2009 Jul;104(7):1737-44
19455118
Lancet. 2003 Jul 5;362(9377):30-7
12853196
Gastroenterology. 1998 Sep;115(3):551-63
9721152
J Clin Pathol. 2006 Oct;59(10):1008-16
17021129
Endocrinology. 1998 Dec;139(12):5034-41
9832442
Nat Rev Immunol. 2002 Sep;2(9):647-55
12209133
Dig Liver Dis. 2007 Sep;39 Suppl 1:S65-71
17936227
Leukemia. 2006 Jun;20(6):1145-54
16617326
N Engl J Med. 2007 Oct 25;357(17):1731-43
17960014
FEBS Lett. 2009 May 6;583(9):1511-5
19364504
J Endocrinol. 2001 Jun;169(3):453-9
11375115
Proteome Sci. 2009 Mar 19;7:10
19298663
Immunity. 2004 Sep;21(3):367-77
15357948
Nat Genet. 2007 Jul;39(7):827-9
17558408
Nat Med. 1998 Jun;4(6):713-7
9623982
Immunity. 2004 Sep;21(3):357-66
15357947
Pharmacol Res. 2005 Feb;51(2):85-94
15629253
Physiol Behav. 2008 May 23;94(2):187-97
18191967
J Biol Chem. 1997 Oct 3;272(40):25252-9
9312141
Lancet. 2000 Jul 15;356(9225):203-8
10963198
Dig Dis Sci. 2006 Oct;51(10):1862-8
16964549
Gut. 1989 Mar;30(3):347-54
2565279
J Proteome Res. 2009 Jan;8(1):170-7
19072164
Gut. 2006 Sep;55(9):1341-9
16905700